BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30883012)

  • 1. Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events.
    Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Koizumi T; Oguchi K
    Thorac Cancer; 2019 Apr; 10(4):980-987. PubMed ID: 30883012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients.
    Lim CH; Ahn TR; Moon SH; Cho YS; Choi JY; Kim BT; Lee KH
    Eur Radiol; 2019 Apr; 29(4):1903-1911. PubMed ID: 30315418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions.
    Basu S; Kung J; Houseni M; Zhuang H; Tidmarsh GF; Alavi A
    Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):9-19. PubMed ID: 18337683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
    Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
    Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
    Koizumi T; Fukushima T; Gomi D; Kobayashi T; Sekiguchi N; Mamiya K; Tateishi K; Katou A; Oguchi K
    Med Oncol; 2017 Sep; 34(10):169. PubMed ID: 28864950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of FDG-PET findings of brain metastasis from non-small-cell lung cancer and small-cell lung cancer.
    Lee HY; Chung JK; Jeong JM; Lee DS; Kim DG; Jung HW; Lee MC
    Ann Nucl Med; 2008 May; 22(4):281-6. PubMed ID: 18535878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
    Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
    Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of pre-treatment
    Aktan M; Koc M; Kanyilmaz G; Yavuz BB
    Ann Nucl Med; 2017 Jul; 31(6):462-468. PubMed ID: 28516335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
    Ding CY; Guo Z; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
    Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
    Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor metabolism measured by partial volume corrected standardized uptake value varies considerably in primary and metastatic sites in patients with lung cancer. A new observation.
    Bural G; Torigian DA; Houseni M; Basu S; Srinivas S; Alavi A
    Hell J Nucl Med; 2009; 12(3):218-22. PubMed ID: 19936331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?
    van der Leest C; Smit EF; Baas J; Versteijlen RJ; van Walree N; Hoogsteden HC; Aerts JG
    Lung Cancer; 2012 Apr; 76(1):67-71. PubMed ID: 21996089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Study of Serial
    Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
    J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter-heterogeneity and intra-heterogeneity of α
    Kang F; Wang Z; Li G; Wang S; Liu D; Zhang M; Zhao M; Yang W; Wang J
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1520-1528. PubMed ID: 28405726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
    Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J
    J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
    Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
    Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.